产品
编 号：F029836
分子式：C17H19Br2NO
分子量：413.15
分子式：C17H19Br2NO
分子量：413.15
产品类型
规格
价格
是否有货
结构图
CAS No: 108179-91-5
产品详情
生物活性：
SKF-83566 hydrobromide is a potent,?blood-brain permeable and orally active D1-like dopamine receptor (D1DR)?antagonist and a weaker competitive antagonist at the vascular 5-HT2?receptor (Ki=11 nM). SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50?of 5.7 μM. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta. SKF-83566 can be used for the research of parkinson’s disease and nicotine craving alleviation.
体内研究：
SKF 83566 hydrobromide (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).Animal Model:Male C57BL6/J mice (6- to 9-wk-old)
Dosage:20 μg/mL (Together with nicotine for 7 d, followed by the injection of cocaine)
Administration:Oral administration; 7 days
Result:Blocked nicotine and cocaine-induced facilitation of LTP.
体外研究：
SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA]o)?evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA]o with 5 μM. The EC50 value of this effect of SKF-83566 is 1.3 μM.SKF-83566 inhibited [3H]DA uptake with an IC50?of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [3H]CFT, a cocaine analog, with an IC50?of 0.51 μM in [3H]DA uptake and [3H]CFT binding studies.Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [3H]CFT binding with an IC50?of 0.77 μM in LLc-PK-rDAT cell membrane preparations.
SKF-83566 hydrobromide is a potent,?blood-brain permeable and orally active D1-like dopamine receptor (D1DR)?antagonist and a weaker competitive antagonist at the vascular 5-HT2?receptor (Ki=11 nM). SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50?of 5.7 μM. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta. SKF-83566 can be used for the research of parkinson’s disease and nicotine craving alleviation.
体内研究：
SKF 83566 hydrobromide (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).Animal Model:Male C57BL6/J mice (6- to 9-wk-old)
Dosage:20 μg/mL (Together with nicotine for 7 d, followed by the injection of cocaine)
Administration:Oral administration; 7 days
Result:Blocked nicotine and cocaine-induced facilitation of LTP.
体外研究：
SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA]o)?evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA]o with 5 μM. The EC50 value of this effect of SKF-83566 is 1.3 μM.SKF-83566 inhibited [3H]DA uptake with an IC50?of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [3H]CFT, a cocaine analog, with an IC50?of 0.51 μM in [3H]DA uptake and [3H]CFT binding studies.Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [3H]CFT binding with an IC50?of 0.77 μM in LLc-PK-rDAT cell membrane preparations.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备